APG-2575
Phase 3Small molecule
Ascentage Pharma Group Inc.APG-2575 is one of 158 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.
5
Indications
11
Total Trials
7
Active Trials
157
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1APG-2575
Ascentage Pharma Group Inc.Phase 3
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Megace
Bristol-Myers SquibbPreclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Apatinib Mesylate
BBukwang Pharmaceutical
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma2 trials
Hematologic Malignancies2 trials
Breast Cancer1 trial
Neuroblastoma1 trial
4 more indications
Age1 trial
Acute Myeloid Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for APG-2575. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company